Cardiotoxicity associated with trastuzumab to treatment of metastatic breast cancer
- At: 2007 FIP Congress in Beijing (China)
- Type: Poster
- By: HUANG, Shiao feng (Chi-Mei medical center, Tainan, China Taiwan)
- Co-author(s): Chen, Lie-Fang (Chi-Mei medical center, TAINAN, China Taiwan)
Trastuzumab is a monoclonal antibody that specifically targets HER-2 positive breast cancer cells. Trastuzumab combined with chemotherapy increases response rates, time to disease progression and survival, but cardiotoxicity has been reported to occurs with Trastuzumab when administered alone and in combination with antineoplastic agents,.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.